VanEck Pharmaceutical ETF
PPH
45 hedge funds and large institutions have $85.5M invested in VanEck Pharmaceutical ETF in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 14 reducing their positions, and 8 closing their positions.
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
2% more funds holding
Funds holding: 44 → 45 (+1)
4.66% less ownership
Funds ownership: 44.28% → 39.62% (-4.7%)
29% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 14
30% less capital invested
Capital invested by funds: $122M → $85.5M (-$36.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCI
Brinker Capital Investments
Berwyn,
Pennsylvania
|
+$8.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$3.43M |
| 3 |
Cerity Partners
New York
|
+$1.28M |
| 4 |
FA
Fortis Advisors
Wayne,
Pennsylvania
|
+$759K |
| 5 |
NL
NVWM LLC
Yardley,
Pennsylvania
|
+$482K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$12.1M |
| 2 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$6.61M |
| 3 |
Goldman Sachs
New York
|
-$6.06M |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$5.09M |
| 5 |
SG Americas Securities
New York
|
-$3.22M |
PPH Hedge Fund Activity: Q4 2018 in Review
45 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q4 2018, worth a combined $85.5M — down 30% from $122M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new PPH positions and 8 closed out — a net gain of 1 holder — while 10 added to existing stakes and 14 trimmed.
The largest buyer was Brinker Capital Investments, opening a new position worth an estimated $8.9M. The largest seller was Citigroup, cutting an estimated $12.1M.
- 45 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q4 2018, up from 44 in Q3 2018.
- Funds reported $85.5M of VanEck Pharmaceutical ETF stock for Q4 2018, down 30% quarter-over-quarter.
- 9 funds opened new VanEck Pharmaceutical ETF positions in Q4 2018 and 8 closed out, a net change of +1 holder.
- The largest VanEck Pharmaceutical ETF buyer in Q4 2018 was Brinker Capital Investments, an estimated $8.9M added.
- The largest VanEck Pharmaceutical ETF seller in Q4 2018 was Citigroup, an estimated $12.1M sold.
Based on aggregated 13F filings for Q4 2018.